Email This Article

Headlines & Perspectives
Orexigen to Post Obesity Data in Race With Vivus, Arena
By Adam Feuerstein
01/06/09 - 04:20 PM EST
Orexigen Therapeutics is expected to release the first phase III data on its experimental weight-loss drug Contrave ahead of a key investor presentation Monday.
Recipient's Email Address(es)
(Separate multiple addresses with a comma)
Your Email Address
Send a copy to myself
Your Message (optional)

Privacy Policy

The information entered on this page will not be used to send unsolicited email and will not be sold to a 3rd party.

Dow Jones S&P 500 NASDAQ 10-Year Note
10,283.09 1,097.79 2,163.12 34.74
Oil *
77.95
UP
36.12
UP
4.78
UP
12.04
DOWN
0.08
10 Yr
3.47%
SPDR Gold
109.35
+0.35%
+0.44%
+0.56%
-0.23%
Data delayed 20 minutes

Brokerage Partners